Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AstroStem in Alzheimer's Disease
NCT03117738Phase 2Completed
- Sponsor
- NatureCell
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AstroStem with Placebo (2 arms). Primary endpoints: Treatment Related Adverse Events at 30 weeks and Alzheimer's Disease Assessment Scale-cognitive Subscale at 30 weeks. Started May 2017; status: completed.
02
Drugs
astrostem
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03117738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117738.